Joseph P. Sanderson
Milton Park
Abingdon, ENG, United Kingdom
Abingdon, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.
Journal: Cancer treatment reviews
Published: November 15, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.
Journal: Molecular therapy. Methods & clinical development
Published: September 29, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: October 25, 2022
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Journal: Nature medicine
Published: December 09, 2021
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Journal: Frontiers in oncology
Published: November 19, 2021
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 02, 2020
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate.
Journal: Oncoimmunology
Published: June 12, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Journal: Hepatology (Baltimore, Md.)
Published: June 07, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.
Journal: PloS one
Published: May 17, 2018
The Clonal Invariant NKT Cell Repertoire in People with Type 1 Diabetes Is Characterized by a Loss of Clones Expressing High-Affinity TCRs.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 11, 2016
Last Updated: 09/26/2026